menu

CME: Expert Answers to Common Questions for Optimizing First-Line Treatment Selection in Advanced Ovarian Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Expert Answers to Common Questions for Optimizing First-Line Treatment Selection in Advanced Ovarian Cancer

Program Information
Recommended
Expert Answers to Common Questions for Optimizing First-Line Treatment Selection in Advanced Ovarian Cancer
RestartResume
Emerging clinical data has uncovered a new treatment option for our patients with advanced ovarian cancer. How can we put it to practice?

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • In Partnership with

  • Overview

    There are limited treatment options in the first-line setting for patients with advanced ovarian cancer. Many patients experience disease recurrence or progression with first-line chemotherapy, with approximately 10% to 30% experiencing long-term survival.

    Anti-angiogenesis agents, such as bevacizumab and nintedanib, have been investigated in clinical trials for the first-line treatment of patients with advanced ovarian cancer. Bevacizumab is now FDA approved in combination with carboplatin and paclitaxel, followed by bevacizumab as a single agent, for the treatment of women with stage III or stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection.

    AXIS routinely collects and analyzes data gathered from participants in our live grand rounds programs. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment planning to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent grand rounds series on anti-angiogenesis agents for the first-line treatment of advanced ovarian cancer.

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to:

    • Assess data from recent clinical trials and guideline recommendations incorporating anti-angiogenesis agents and other novel therapies as first-line treatment for patients with advanced ovarian cancer.
    • Apply evidence-based clinical data demonstrating the benefit of anti-angiogenesis agents in specific patient populations to select treatment for patients with advanced ovarian cancer.
  • Target Audience

    This activity is intended for medical oncologists, gynecologic oncologists, gynecologists, and other healthcare professionals treating advanced stage ovarian cancer.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

    AXIS will identify, review, and resolve all conflicts of interestthat faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:  Bradley Monk, MD, FACS, FACOG, reported a financial interest/relationship or affiliation in the form of Consultant, Merck & Co, Inc, Tesaro, Inc, Advaxis, Inc, Clovis Oncology, Mateon (Oxigene, Inc), Genentech/Roche, AstraZeneca Pharmaceuticals LP, Pfizer, Inc, Perthera, ImmunoGen, Genmab, Myriad Genetics, Inc, VBL, Janssen Pharmaceuticals, Inc - a pharmaceutical company of Johnson & Johnson; Speaker, Tesaro, Inc, Clovis Oncology, Genentech/Roche, AstraZeneca Pharmaceuticals LP, Janssen Pharmaceuticals, Inc - a pharmaceutical company of Johnson & Johnson.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planner and manager, Jocelyn Timko, BS  hereby state that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Linda Gracie-King, MS reports her spouse has a financial interest/relationship or affiliation in the form of Common stock, Exelixis. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock, Merck.

  • Accreditation and Credit Designation Statements

    Accreditation Statement

     

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AXIS Contact Information
    For information about the certification of this activity, please contact AXIS at info@axismeded.com

  • Provided By

  • Commercial Support

    Supported by an educational grant from Genentech.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Method of Participation and Request for Credit

    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. 

  • Fee

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/22/19

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.